Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CORVUS PHARMACEUTICALS, INC.

(CRVS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Corvus Pharmaceuticals Provides Updates on Mupadolimab

09/22/2021 | 06:00am EST

Corvus Pharmaceuticals provided an update on its development programs in oncology and infectious disease for mupadolimab (formerly CPI-006), a humanized monoclonal antibody directed against CD73 with a proposed dual mechanism of activating B cells to generate immune responses to viruses and tumor antigens, and inhibiting the production of immunosuppressive adenosine in the tumor micro environment. Corvus is developing mupadolimab as a therapeutic for oncology indications and for infectious disease, starting with COVID-19. the Company announced results from its Phase 3 clinical trial of mupadolimab for COVID-19, which have been published online at medRxiv.org. The results, which cover 40 patients that were enrolled in the trial prior to its voluntary discontinuation, suggest improvement in the primary and key secondary endpoints in patients treated with single doses of mupadolimab at 2mg/kg and 1mg/kg compared to placebo. No drug related adverse events were reported in the trial. Mupadolimab also is currently being studied in a Phase 1b/2 clinical study in patients with HPV+ oropharyngeal cancers and non small cell lung cancers (NSCLC) that have failed previous treatment with anti-PD-1 therapy and chemotherapy. Data from the Phase 1b/2 clinical study has been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) annual meeting in November.


© S&P Capital IQ 2021
All news about CORVUS PHARMACEUTICALS, INC.
11/12Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Cl..
GL
11/10Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
GL
11/02Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society ..
GL
11/02CORVUS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial State..
AQ
11/01CORVUS : Q3 Earnings Snapshot
AQ
11/01Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financia..
PU
11/01CORVUS PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
11/01Earnings Flash (CRVS) CORVUS PHARMACEUTICALS Reports Q3 Loss $-0.24
MT
11/01Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
11/01Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financia..
GL
More news
Analyst Recommendations on CORVUS PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -42,5 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,88x
Yield 2021 -
Capitalization 159 M 159 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 42
Free-Float 89,4%
Chart CORVUS PHARMACEUTICALS, INC.
Duration : Period :
Corvus Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORVUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 3,41 $
Average target price 5,13 $
Spread / Average Target 50,3%
EPS Revisions
Managers and Directors
Richard A. Miller Chairman, President & Chief Executive Officer
Leiv Lea Chief Financial Officer
Suresh Mahabhashyam Vice President-Clinical Development
Peter A. Thompson Independent Director
Elisha P. Gould Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CORVUS PHARMACEUTICALS, INC.-4.21%159
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431